2011
DOI: 10.1155/2011/159436
|View full text |Cite
|
Sign up to set email alerts
|

Prophylaxis of Macular Edema with Intravitreal Ranibizumab in Patients with Diabetic Retinopathy after Cataract Surgery: A Pilot Study

Abstract: The purpose of this study was to evaluate the effectiveness of intravitreal ranibizumab (Lucentis, Genentech, South San Francisco, Calif, USA) combined with cataract surgery for the prevention of clinically significant macular edema (CSME) in patients with diabetic retinopathy (DR). This prospective interventional case series included fifty-four eyes of 54 patients with a previous diagnosis of nonproliferative diabetic retinopathy (NPDR) without macular edema preoperatively. Subjects were assigned in a 1 : 1 r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
17
0
2

Year Published

2012
2012
2022
2022

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 24 publications
(19 citation statements)
references
References 17 publications
0
17
0
2
Order By: Relevance
“…In addition, Muether et al used Luminex technology to measure VEGF suppression in the aqueous humor and showed that the therapeutic effect disappeared after 33.7 ± 5.1 days when they analyzed samples obtained during cataract surgery [ 8 ]. Prophylaxis of DME after cataract surgery with intravitreal RAN in patients with DR has been shown in previous studies, although, owing to the short half-life, the effect is transient and could show individual changes [ 9 , 10 ].…”
Section: Introductionmentioning
confidence: 99%
“…In addition, Muether et al used Luminex technology to measure VEGF suppression in the aqueous humor and showed that the therapeutic effect disappeared after 33.7 ± 5.1 days when they analyzed samples obtained during cataract surgery [ 8 ]. Prophylaxis of DME after cataract surgery with intravitreal RAN in patients with DR has been shown in previous studies, although, owing to the short half-life, the effect is transient and could show individual changes [ 9 , 10 ].…”
Section: Introductionmentioning
confidence: 99%
“…Известно, что использование инъекций КС приводит к повышению внутриглазного давления (ВГД) [51] и сопровождается гипергликемией у больных СД [52], поэтому их применение сопряжено с определенными рисками. С помощью анти-VEGF-препаратов не удалось достичь статистически значимого эффекта, хотя в литературе описываются случаи их успешного применения с целью предотвращения КМО [53,54].…”
Section: обоснованная профилактика макулярного отека после хирургии кunclassified
“…Че-рез 1 мес после операции частота клинически значимого макулярного отека в группе плацебо составила 25,92%, в основной группе -3,70%, а через 3 мес -22,22% и 3,70% соответственно [38].…”
Section: интравитреальное применение ингибиторов Vegfunclassified